Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Solid Tumor Malignancies
Open-data reference.
12 US clinical trials · 11 currently recruiting
Active & Recent Trials
PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival
UNC Lineberger Comprehensive Cancer Center
NCT06896162
Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Vir Biotechnology
NCT06960395
xDRIVE for Florida-based Cancer Patients
First Ascent Biomedical
NCT07167381
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
Phrontline Biopharma
NCT07181473
Trial to Evaluate irAEs With Different Standard of Care Dosing Strategies of Standard of Care Immunotherapies
University of Kansas Medical Center
NCT07174453
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Tasca Therapeutics
NCT07030257
A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
Kumquat Biosciences
NCT06720987
A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases
A2A Pharmaceuticals
NCT06136884
A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
Kumquat Biosciences
NCT06994806
A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies
Kumquat Biosciences
NCT07207707
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
Rigel Pharmaceuticals
NCT07486713
ProAgio in Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies
ProDa BioTech
NCT05085548
Phase Distribution
| Phase | Trial count |
|---|---|
| Early Phase 1 | 8 |
| Phase 3 | 1 |
| Phase 4 | 1 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Reading the Solid Tumor Malignancies Trial Landscape
ClinicalTrials.gov lists 12 US studies indexed under Solid Tumor Malignancies, and 11 of those are currently open to recruitment — roughly 92% of the total volume on the registry. That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.
The phase distribution for Solid Tumor Malignancies shows 2 late-stage studies (Phase 3 and Phase 4 combined) alongside 8 earlier-phase entries (Phase 1 through Phase 2). Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.
Top sponsor activity for Solid Tumor Malignancies is led by Kumquat Biosciences with 3 indexed trials, alongside 9 other organizations in the top contributor list. The list on this page surfaces up to 12 of the most relevant recent and active entries, ordered with recruiting studies first so practical options are visible. All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation — eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.
Frequently Asked Questions
How many clinical trials are there for Solid Tumor Malignancies?
PlainTrial tracks 12 US clinical trials for Solid Tumor Malignancies, of which 11 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Solid Tumor Malignancies?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology — how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2024 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.